Pila Pharma doses first participants in obesity trial with oral TRPV1 antagonist

2026-10-14 14:06:00

Less than two weeks after activating its clinical site, Pila Pharma has dosed the first two participants in its 12-week obesity trial. The study evaluates the oral drug candidate XEN-D0501 at doses up to four times higher than previously tested in humans. To manage the escalation safely, the trial kicks off with a smaller pilot cohort before expanding to the full patient group.

Read the full article at biostock.se:
https://biostock.se/en/2026/10/pila-pharma-doses-first-participants-in-obesity-trial-with-oral-trpv1-antagonist/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital.